Monday, September 1, 2014
Inquirer Daily News

Daniel Hoffman

What's driving Pharma's international bribery scandals?

Thursday, April 10, 2014, 10:44 AM
Last year the authorities in China exposed a pattern of systematic corruption by GlaxoSmithKline (GSK) and other pharma companies. Labeled as "Chinagate" in the media, it involved senior pharma managers in China that routinely bribed physicians, hospital administrators and government officials to... Read more

War of Each Against All Is a Good Thing

Monday, March 31, 2014, 6:00 AM
Last week Merck and GlaxoSmithKline (GSK) announced they will suspend co-pay cards because, under the Affordable Care Act, these cards could constitute a possible kickback and expose the pharma companies to legal liability (see here). Therein hangs a tale. First, here's a bit of background on these... Read more

Corporate players in Health Care try to prevent a real market

Monday, March 17, 2014, 9:34 AM
A survey of 595 employers, each with 1,000 or more employees, by consultancy Towers-Watson (see here) showed that: (1) employers are shifting more costs to workers in the form of higher premiums and more out-of-pocket payments, (2) fewer and fewer employer plans will cover spouses/families, (3) subsidized... Read more

Realities Starting to Dispel Pharma's BRIC and Biosimilar Myths

Thursday, March 6, 2014, 9:13 AM
Recently there's been some discussion in pharma's higher circles that biosimilars may not offer the road to riches along the lines touted by the industry's C-suite officers. It is becoming increasingly clear that only a few companies may make substantial profits in that area and, in fact, biosimilars... Read more

What will co-insurance mean for Pharma?

Wednesday, February 26, 2014, 6:00 AM
Last week the health care policy consultancy, Avalere Health, predicted that within a couple of years, most of the insurance plans obtained through the exchanges established by the Affordable Care Act will require consumers to pay a percentage of the costs—rather than fixed co-payments—for... Read more

What's driving the pharmaceutical industry's drug development process?

Tuesday, February 18, 2014, 6:00 AM
Over the last several years some widely discernible trends of the pharmaceutical industry's drug development process have emerged. Much of this is driven by three factors. The first is that a declining percentage of the drugs produced by research constitute genuine breakthroughs capable of substantially... Read more

Drug prices: Higher and higher

Thursday, January 30, 2014, 11:59 AM
In an effort save money on continually rising drug costs, the Germans passed the Reform of the Market for Medicinal Products act in 2010 to assess whether newly approved brands in that country justify their higher prices with greater benefits than older products. Germany's Federal Joint Committee... Read more

Pharma's 2014 outlook and Merck's changing culture

Monday, January 20, 2014, 10:35 AM
Citigroup recently issued its 2014 outlook for European and US pharmaceutical companies. While their outlook is generally bullish, the positive signs they emphasize for the industry are more notable for what they omit than for what they tout. For example, some of their up-indicators include a more... Read more

Challenges for Merck's Venture in Weight Loss Management

Thursday, January 9, 2014, 6:00 AM
In the week before Christmas, Merck announced (see here) that it was starting a weight loss business as a self-supporting enterprise. In the past, whenever pharmas launched businesses outside of prescription and non-prescription pharmaceuticals, they were typically "value-added" enterprises designed... Read more

A lesson from not prosecuting the banks

Tuesday, December 31, 2013, 6:00 AM
Anyone who's been awake the past five years knows that the U.S. experienced its worst economic recession since the 1930s as a result of fraudulent manipulations by investment banks and other financial institutions. Equally galling has been the lack of criminal action against these Wall Street fraudsters... Read more
About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Also on Philly.com:
Stay Connected